(In United States dollars, except where noted otherwise) TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- First Quantum Minerals Ltd. (“First Quantum” or the "Company”) (TSX: FM) today reports results for the three months ended March 31, 2025 (“Q1 2025” or the "first quarter") of net loss attributable to shareholders of the Company of $23 million ($0.03 loss per share) and adjusted earnings1 of $2 million ($0.00 adjusted earnings per share2). “Kansanshi and Sentinel held up well in the first quarter and we remai ...

Core Points - West Fraser Timber Co. Ltd. held its Annual General Meeting on April 23, 2025, in Quesnel, B.C., where shareholders voted on various matters [1]. Voting Results for the Election of Directors - A total of 60,282,131 shares were voted, representing 75.75% of all outstanding shares [2]. - All director nominees were elected with significant support, including: - Hank Ketcham: 90.39% in favor - Doyle N. Beneby: 96.27% in favor - Eric L. Butler: 99.91% in favor - Reid E. Carter: 98.40% in favor - John N. Floren: 98.97% in favor - Ellis Ketcham Johnson: 98.86% in favor - Brian G. Kenning: 96.71% in favor - Marian Lawson: 99.90% in favor - Sean P. McLaren: 99.93% in favor - Colleen M. McMorrow: 99.93% in favor - Janice G. Rennie: 90.16% in favor - Gillian D. Winckler: 99.58% in favor [2]. Voting Results for Other Matters - Shareholders approved the number of directors to be fixed at twelve [3]. - PricewaterhouseCoopers LLP was appointed as the auditor of the Company [3]. - The resolution on executive compensation (Say-on-Pay) was approved with 90.04% of votes in favor [3]. Company Overview - West Fraser is a diversified wood products company with over 50 facilities across Canada, the United States, the United Kingdom, and Europe [5]. - The Company produces a variety of products including lumber, engineered wood products, pulp, and newsprint, which are utilized in home construction, industrial applications, and paper products [5].

Group 1 - AutoZone appointed Claire Rauh McDonough to its Board of Directors, expanding the board to 10 members [1][3] - Claire Rauh McDonough is currently the Chief Financial Officer of Rivian and has a background in investment banking, previously serving as a Managing Director at J.P. Morgan [2] - The addition of McDonough is expected to enhance the board's perspectives and deliberations, according to Bill Rhodes, Executive Chairman of AutoZone [3] Group 2 - As of February 15, 2025, AutoZone operates a total of 7,432 stores, with 6,483 in the U.S., 813 in Mexico, and 136 in Brazil [4] - AutoZone is a leading retailer and distributor of automotive replacement parts and accessories in the Americas, offering a wide range of products for various vehicle types [5] - The company provides commercial sales programs and online purchasing options for both retail and commercial customers, without deriving revenue from automotive repair or installation services [5]

TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation”) (SVI-TSX) reported the Corporation’s 2025 first quarter results, completes another 100,000 square feet of new space, announces $126.2 million of acquisitions and increases dividend. Iqbal Khan, Chief Financial Officer, commented: “We are pleased to start the year off with positive same store revenue and NOI growth leading to AFFO per common share growth of 4.2%. In addition, we completed 100,000 square ...

Not for Distribution to U.S. Newswire Services or for Dissemination in the United States of America. TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Picton Mahoney Asset Management (“Picton Mahoney”), the manager of the Picton Mahoney Fortified Market Neutral Alternative Fund (TSX: PFMN) and the Picton Mahoney Fortified Inflation Opportunities Alternative Fund (collectively, the “Funds”), announced that effective today, the risk ratings of the Fund have changed as follows: FundNew Risk RatingPrevious Risk Ratin ...

BOCA RATON, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the first quarter ended March 31, 2025, after the market closes on Thursday, May 8, 2025. Management will host a conference call and audio webcast on Thursday, May 8, 2025, at 4:30 p.m. ET to discuss the Company’s financial results. Event:First Quarter 2025 Financia ...

DALLAS, April 23, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben,” or the “Company”), a technology-enabled platform providing exit opportunities, primary capital solutions, and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, reminds stockholders to vote on proxy proposals before the upcoming Annual Meeting of Stockholders at 9:00 a.m. Central Time on April 30, 2025. Stockholders who have not yet voted are encou ...

Core Insights - Insmed Incorporated announced positive results from the pivotal phase 3 ASPEN study of brensocatib, demonstrating a statistically significant reduction in pulmonary exacerbations in patients with non-cystic fibrosis bronchiectasis [1][2] - Brensocatib is currently under Priority Review with the U.S. FDA, with a target action date of August 12, 2025 [5] Study Results - The ASPEN study is the largest clinical trial ever conducted in bronchiectasis, involving 1,680 adult patients and 41 adolescent patients across 391 sites in 35 countries [6][7] - The annualized rate of pulmonary exacerbations was significantly lower in the brensocatib groups: 1.02 for 10 mg, 1.04 for 25 mg, compared to 1.29 for placebo, with rate ratios of 0.79 (P=0.004) and 0.81 (P=0.005) respectively [2][3] - Both dosage strengths of brensocatib also met secondary endpoints, including prolonging time to first exacerbation and increasing the proportion of patients remaining exacerbation-free [3] Safety and Tolerability - Brensocatib was well-tolerated, with treatment-emergent adverse events (TEAEs) occurring in at least 5% of patients, including COVID-19, nasopharyngitis, cough, and headache [4] Market Potential - Approximately 500,000 patients in the U.S., 600,000 in the EU5, and 150,000 in Japan are diagnosed with bronchiectasis, highlighting a significant unmet medical need [7] - Brensocatib has the potential to be the first approved therapy for bronchiectasis and the first DPP1 inhibitor, addressing a range of neutrophil-mediated inflammatory diseases [5][8] Company Overview - Insmed is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for serious diseases, with a diverse portfolio of investigational medicines [9][10]

Core Viewpoint - Beneficient is urging stockholders to participate in the upcoming Annual Meeting by voting on proxy proposals, emphasizing the importance of their votes for meeting quorum requirements [1][4]. Company Overview - Beneficient (NASDAQ:BENF) is a technology-enabled platform that provides exit opportunities, primary capital solutions, and related trust and custody services for holders of alternative assets through its online platform, AltAccess [1][5]. - The company aims to democratize the global alternative asset investment market, targeting mid-to-high net worth individuals, small-to-midsized institutions, and General Partners [5]. Voting Information - Stockholders are encouraged to vote by 11:59 p.m. Central Time on April 29, 2025, through various methods including online, telephone, or by mailing a proxy card [2]. - The Annual Meeting will be held virtually on April 30, 2025, at 9:00 a.m. Central Time [1][2]. Proxy Solicitation - The company continues to solicit proxies for the proposals outlined in its proxy statement, and votes already submitted will be counted unless revoked [3]. - The Board of Directors recommends that stockholders vote in favor of all proposals, believing they are in the best interests of the company and its stockholders [4]. Regulatory Information - Beneficient Fiduciary Financial, L.L.C., a subsidiary of the company, has received its charter under the State of Kansas' Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight [6]. Additional Information - The company has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) regarding the Annual Meeting, and stockholders are urged to read all relevant documents before making voting decisions [7].

Core Viewpoint - Aptose Biosciences Inc. announced that KPMG LLP will not stand for re-appointment as the independent registered public accounting firm for the 2025 annual audit, while KPMG will continue to review the company's quarterly interim financial results through the first two fiscal quarters of 2025 [1]. Group 1: Company Announcement - KPMG did not seek the company's consent regarding its decision not to stand for re-appointment, and neither the Board of Directors nor the Audit Committee participated in this decision [2]. - KPMG issued unqualified reports on the company's consolidated financial statements for the fiscal years ended December 31, 2024, and 2023 [3]. - There were no disagreements or reportable events between the company and KPMG during the fiscal years ended December 31, 2024, and 2023, except for a communicated material weakness in internal control over financial reporting related to complex financial instruments [4]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [6]. - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [6].